Sensorion SA banner

Sensorion SA
PAR:ALSEN

Watchlist Manager
Sensorion SA Logo
Sensorion SA
PAR:ALSEN
Watchlist
Price: 0.614 EUR 5.86% Market Closed
Market Cap: €316.2m

Sensorion SA
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sensorion SA
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Sensorion SA
PAR:ALSEN
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Inventory
€64.3m
CAGR 3-Years
22%
CAGR 5-Years
19%
CAGR 10-Years
9%
G
Genfit SA
PAR:GNFT
Inventory
€4k
CAGR 3-Years
0%
CAGR 5-Years
-17%
CAGR 10-Years
-28%
Inventiva SA
PAR:IVA
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abivax SA
PAR:ABVX
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sensorion SA
Glance View

Market Cap
316.2m EUR
Industry
Biotechnology

Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 34 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.

ALSEN Intrinsic Value
0.099 EUR
Overvaluation 84%
Intrinsic Value
Price

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett